Last reviewed · How we verify
Cosopt PF 2%-0.5% Ophthalmic Solution
Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production.
Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Cosopt PF 2%-0.5% Ophthalmic Solution |
|---|---|
| Sponsor | Prairie Eye Center |
| Drug class | Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker |
| Target | Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dorzolamide inhibits carbonic anhydrase in the ciliary body, reducing aqueous humor secretion. Timolol is a non-selective beta-adrenergic antagonist that further decreases aqueous humor production and may increase uveoscleral outflow. Together, these dual mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular burning or stinging
- Blurred vision
- Tearing
- Corneal erosion
- Headache
Key clinical trials
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cosopt PF 2%-0.5% Ophthalmic Solution CI brief — competitive landscape report
- Cosopt PF 2%-0.5% Ophthalmic Solution updates RSS · CI watch RSS
- Prairie Eye Center portfolio CI